Eckelman Brendan P. 13D and 13G filings for Inhibrx Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:12 pm Sale |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Eckelman Brendan P. | 2,397,219 5.100% |
-352,734 (-12.83%) |
Filing |
| 2021-02-12 4:38 pm Purchase |
2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Eckelman Brendan P. | 2,749,953 7.300% |
2,749,953 (New Position) |
Filing |